<DOC>
	<DOCNO>NCT02354586</DOCNO>
	<brief_summary>This Phase 2 , open-label , single arm study evaluate safety efficacy niraparib ovarian cancer patient receive three four previous chemotherapy regimen . Niraparib orally active PARP inhibitor . Niraparib administer daily continuously 28-day cycle . Health-related quality life measure Eastern Cooperative Oncology Group performance status ( ECOG ) . Safety tolerability assess clinical review adverse event ( AEs ) , physical examination , electrocardiogram ( ECGs ) , RECIST tumor assessment safety laboratory value .</brief_summary>
	<brief_title>A Study Niraparib Patients With Ovarian Cancer Who Have Received Three Four Previous Chemotherapy Regimens</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Patients must agree undergo tumor HRD test blood gBRCAmut status test . Patients childbearing potential must negative pregnancy serum test within 72 hour dosed Patients must histologically diagnose highgrade ( Grade 2 3 ) serous epithelial ovarian , fallopian tube , primary peritoneal cancer recurrent disease must previously treat chemotherapy experienced response last least 6 month firstline platinum base therapy . Patients Must complete 3 4 previous chemotherapy regimen . Patients must complete last chemotherapy regimen &gt; 4 week prior treatment initiation . Patients must measurable disease accord RECIST ( v.1.1 ) . Patients must formalinfixed , paraffinembedded tumor sample available primary recurrent cancer agree undergo fresh biopsy prior study treatment initiation . Patients must agree blood sample screen end treatment cytogenetic analysis . Patients must know , persistent ( &gt; 4 week ) , â‰¥Grade 3 hematologic toxicity fatigue prior cancer therapy require treatment transfusion growth factor 1 occasion within 1 year prior study therapy . Patients must receive pelvic radiotherapy treatment primary recurrent disease within 1 year first dose study treatment . Patients must symptomatic uncontrolled brain leptomeningeal metastasis . Patients must consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Patients must receive transfusion ( platelet red blood cell ) within 4 week first dose study treatment . Patients must know history current diagnosis myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( AML ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>gBRCAmut</keyword>
	<keyword>BRCA</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>HRD</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Serous Epithelial</keyword>
	<keyword>Fallopian Tube</keyword>
	<keyword>Primary Peritoneal</keyword>
</DOC>